Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Bicara Therapeutics Inc. (BCAX : NSDQ)

• Company Description    Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. The company's lead asset includes ficerafusp alfa. Bicara Therapeutics Inc. is based in BOSTON. Number of Employees: 55

• Price / Volume Information    Yesterday's Closing Price: $14.64 Daily Weekly Monthly 20 Day Moving Average: 806,399 shares Shares Outstanding: 54.61 (millions) Market Capitalization: $799.53 (millions) Beta: -0.76 52 Week High: $24.70 52 Week Low: $7.80 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -17.66% -19.82% 12 Week 25.77% 20.56% Year To Date -15.96% -26.54%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 116 Huntington Avenue Suite 703 - Boston,MA 02116 USA ph: 617-468-4219 fax: - ir@bicara.com http://www.bicara.com

• General Corporate Information    Officers Claire Mazumdar - Chief Executive Officer Michael Powell - Chairperson Ryan Cohlhepp - President; Chief Operating Officer Ivan Hyep - Chief Financial Officer Nils Lonberg - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 055477103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 54.61 Most Recent Split Date: (:1) Beta: -0.76 Market Capitalization: $799.53 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.60 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.32 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.83 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 26.47% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -21.67 03/31/25 - -25.29 ROA 09/30/25 - - 06/30/25 - -20.89 03/31/25 - -24.42 Current Ratio 09/30/25 - - 06/30/25 - 25.80 03/31/25 - 24.62 Quick Ratio 09/30/25 - - 06/30/25 - 25.80 03/31/25 - 24.62 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 7.98 03/31/25 - 8.42 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©